RxDoctor Payments Data

Andrew Wetstone, MD

Internal Medicine · Longmeadow, MANPI 1194705228

Payments from drug & device makers

$1,536in general payments, 2019–2025

Across 86 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$407
  • GSK$253
  • Amgen$168
  • AbbVie$157
  • AstraZeneca$124
  • Sanofi-aventis U.S. LLC$95
  • plus $332 from 8 others

What the payments were for

  • Food & beverage$1,52499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,536 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$149,195
Medicare patients
473
Services billed
1,740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban202$213,241
JardianceEmpagliflozin30$38,374
OzempicSemaglutide32$32,678
TrulicityDulaglutide27$31,969
XareltoRivaroxaban34$29,648
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$18,193
FarxigaDapagliflozin Propanediol16$12,289
Atorvastatin Calcium673$11,416
Breo ElliptaFluticasone/Vilanterol18$9,660
Rosuvastatin Calcium256$8,077
Metoprolol Succinate303$7,840
SymbicortBudesonide/Formoterol Fumarate16$6,091
Pravastatin Sodium191$5,244
Losartan Potassium296$4,616
Omeprazole287$3,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$407$213,241202 claims
Boehringer IngelheimJardiance$15$38,37430 claims
Novo NordiskOzempic$47$32,67832 claims
Lilly USA, LLCTrulicity$44$31,96927 claims
GSKTrelegy Ellipta, Breo Ellipta$253$27,85235 claims
AstraZenecaFarxiga, Symbicort$124$18,38032 claims
AbbVieSynthroid$157$2,65641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Longmeadow

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →